Afatinib dimaleate other · Synonyms: BIBW 2992MA2 | BIBW 2992 dimaleate

Afatinib dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family.

For research use only. Not for human or veterinary use.

Target EGFR Autophagy Apoptosisc-Met/HGFR Akt p38 MAPK

Research area Cancer

Purity >99% Stock Inquire

Data Sheet SDS COA

Afatinib dimaleate structure

CAS No.: 850140-73-7

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
1 g	USD 415.00	BP-02089A-1g	In stock	Get quote
2 g	USD 664.00	BP-02089A-2g	In stock	Get quote
3 g	USD 800.00	BP-02089A-3g	In stock	Get quote
5 g	USD 1,060.00	BP-02089A-5g	In stock	Get quote
10 g	USD 1,700.00	BP-02089A-10g	In stock	Get quote
25 g	USD 3,400.00	BP-02089A-25g	In stock	Get quote

Need another size or custom synthesis? Request a quote.

Related forms

BP-02089 — Afatinib

Description

Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer.

Biological activity

In Vitro Afatinib dimaleate (100 nM) sufficiently prevents heregulin-stimulated HER3 phosphorylation. Afatinib dimaleate (0-10000 nM) effectively inhibits anchorage-independent proliferation of NIH-3T3 cells ectopically expressing EGFR mutants, and inhibits cell proliferation of H1666, H3255, and NCI 1975 cells. Afatinib dimaleate (48-72 h)shows growth inhibition in HKESC-1, HKESC-2, SLMT-1 and EC-1 cells. Afatinib dimaleate (0-1 μM, 24-48 h) inhibits AKT and MAPK pathways, and inhibits EGFR and AKT phosphorylation in ESCC cell lines. Afatinib dimaleate (0-1 μM, 16-48 h) induces G0/G1 cell cycle arrest in HKESC-2 and EC-1. Afatinib dimaleate (0-1 μM, 24-48 h) effectively induces apoptotic cell death in HKESC-2 and EC-1. In Vivo Afatinib dimaleate (0-20 mg/kg, Orally, daily for 25 days) shows dramatic tumor regression and downregulation of EGFR, HER2, HER3 and AKT phosphorylation. Afatinib dimaleate (15 mg/kg, Orally, in a schedule of 5 days on plus 2 days off, for two weeks) strongly inhibits the growth of HKESC-2 tumor.

Identifiers

SMILES: C(=C\C(O)=O)\C(O)=O.N(C=1C2=C(C=C(O[C@H]3CCOC3)C(NC(/C=C/CN(C)C)=O)=C2)N=CN1)C4=CC(Cl)=C(F)C=C4
InChIKey: LIENDGDDWJRJLO-WFFUCRSMSA-N

Specifications

MW (average): 718.0830
Formula: C₃₂H₃₃ClFN₅O₁₁
CAS No.: 850140-73-7
Physical state: Solid
Color: white to yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: 4°C, sealed storage, away from moisture

Solubility

Soluble in DMSO : 100 mg/mL H2O : 50 mg/mL

Documents

References

[1]. Li D, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008 Aug 7;27(34):4702-11.

[2]. Wong CH, et al. Preclinical evaluation of afatinib (BIBW2992) in esophageal squamous cell carcinoma (ESCC). Am J Cancer Res. 2015 Nov 15;5(12):3588-99.

[3]. Wang XK, et al. Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo. Oncotarget. 2014 Dec 15;5(23):11971-85.

[4]. Yoshioka T, et al. Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer. Cancer Sci. 2018 Apr;109(4):1166-1176.

Same target

Search EGFR

Same research area

Search Cancer